Kazuhiko Nakagawa, MD, PhD, is a professor in the Department of Medical Oncology, Kindai University, Faculty of Medicine, in Japan, and he served as the lead principal investigator on the […] Read more
Checkpoint Inhibitors in SCLC: Putting the Most Novel Data in Context
Edgardo SantosTwo separate randomized phase III trials have established atezolizumab (IMpower1331 and durvalumab (CASPIAN2) as first-line treatments for extensive-stage (ES) SCLC in combination with chemotherapy followed by these same checkpoint inhibitors (CPIs) […] Read more
Multidisciplinary Tumor Boards: Integrating Best Patient Care and Education in Precision Medicine
Reinhard Büttner, MD+more
One of the pillars of organ-specific tumor centers certified by the German Cancer Society, such as lung, breast, and prostate cancer centers, is a weekly multidisciplinary tumor board (MTD). In […] Read more
Understanding the Promising Role of Stereotactic Ablative Radiotherapy in Treating Patients With Oligometastatic Disease
Arya Amini+more
The recently published long-term results of the SABR-COMET phase II trial have further invigorated treatment options for patients with oligometastatic cancer.1 The early results of the SABR-COMET trial published in […] Read more
The Rationale for Local Consolidation Therapy in Oncogene-Driven NSCLC
Mehmet Altan+more
The availability of effective TKIs for patients with metastatic NSCLC with targetable oncogenes such as EGFR, ALK, ROS1, and BRAF has transformed the treatment landscape, extending median expected OS from […] Read more
University of California, Davis, Thoracic Oncology Innovation Group to Again Host Latin American Oncologists for 3-Day Preceptorship
David R. GandaraDavid R. Gandara, MD, past-president of the IASLC and director of Thoracic Oncology and senior advisor, UC Davis Comprehensive Cancer Center (UCDCCC), has always had a passion for mentorship, largely […] Read more
Cardiac Radiation Dose, Cardiac Events, and Survival in Locally Advanced NSCLC
Megan DalyMegan Daly The standard of care for fit patients with unresectable, locally advanced (LA-) NSCLC is concurrent chemoradiation (CRT) followed by consolidation durvalumab. However, thoracic radiation (RT) for lung cancer […] Read more
October 2, 2020—As part of the U.S. Food and Drug Administration’s (FDA) Project Orbis, the FDA approved combination nivolumab and ipilimumab for treatment-naive patients with unresectable malignant plueral mesothelioma (MPM). […] Read more
Ending Stigma in Lung Cancer: The IASLC Participates in a Collaborative Summit Held by the National Lung Cancer Roundtable
Jill Feldman+more
Stigma is any thinking or behavior that produces internal shame or external judgment toward a person, place, or thing.1 In healthcare, stigma could be any sociocultural norm that prevents a […] Read more
Cell-free RNA Affords Another Tool in Lung Cancer Diagnosis and Treatment Monitoring
Kara Nyberg, PhDAlthough cell-free DNA (cfDNA) has emerged as the favored nucleic acid to analyze in liquid biopsy samples, there are situations when this marker fails to provided necessary information. In such cases, cell-free RNA (cfRNA) might help […] Read more